Press Releases

Press Releases
Date Title and Summary View
Oct 23, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 23, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, will release its third quarter financial results on Tuesday, October 30, 2007 before the market opens. The Company will also hold a conference call on...
Oct 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 17, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced a presentation at CHI's Discovery on Target: Developing Inhibitors for Promising Drug Targets, which is being held at the World ...
Oct 16, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced that Genentech has initiated an expansion cohort in its ongoing Phase I clinical trial of a systemically administered Hedgehog a...
Oct 3, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that the company will be presenting at BIO InvestorForum 2007, which is being held from October 9-11, 2007 at the Palace Hotel in San F...
Sep 25, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today provided an update on CUDC-101 and other preclinical drug candidates under its Targeted Cancer Drug Development Platform. The Company is ...
Aug 28, 2007 CAMBRIDGE, Mass., Aug 28, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that it was notified by one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), that preliminary data wi...
Aug 16, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 16, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that the Company will be presenting at the Noble Financial Equity Two Double------Seven Conference, being held August 20-21, 2007, at t...
Aug 6, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that it has entered into definitive agreements with certain institutional and accredited investors with respect to the private placement...
Jul 31, 2007 CAMBRIDGE, Mass., Jul 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today reported its financial results for the second quarter ended June 30, 2007. For the second quarter of 2007, Curis reported a net loss of $3,998...
Jul 24, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 24, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, will release its second quarter financial results on Tuesday, July 31, 2007 before the market opens. The Company will also hold a conference call on July 31st...
FirstPrevious ...
34
NextLast
Add to Briefcase = add release to Briefcase